Chronic Implantation of Intravascular Cardioverter Defibrillator in a Canine Model by Merkely, Béla Péter et al.
DEVICES
Chronic Implantation of Intravascular Cardioverter
Defibrillator in a Canine Model: Device Stability,
Vascular Patency, and Anchor Histology
BELA MERKELY, M.D., PH.D.,* LEVENTE MOLNAR, M.D.,* LASZLO GELLER, M.D., PH.D.,*
PETR NEUZIL, M.D., PH.D.,† JAN SKODA, M.D.,† JACEK BEDNAREK, M.D., PH.D.,‡
KRZYSZTOF BARTUS, M.D., PH.D.,‡ VIVEK Y. REDDY, M.D.,§
and WILLIAM E. SANDERS JR., M.D., M.B.A.¶
From the *Heart Center, Semmelweis University, Budapest, Hungary; †Hospital Na Homolce, Prague, Czech
Republic; ‡John Paul II Hospital, Jagiellonian University, Krakow, Poland; §Mount Sinai School of Medicine, New
York, New York; and ¶University of North Carolina, Chapel Hill, North Carolina
Introduction: A percutaneously placed implantable intravascular defibrillator (PICD) has been
developed with a right ventricular (RV) single-coil lead and titanium electrodes in the superior vena
cava (SVC) and the inferior vena cava (IVC). This study evaluated implant techniques, device stability,
and anchor histology of the PICD over 9 months in a canine model.
Methods: Twenty-four hounds (wt = 30–55 kg) were anesthetized and a custom sheath introduced into
the right femoral vein. The PICD was advanced over a wire and positioned with the titanium electrodes
(cathodes) in the SVC and the IVC. A nitinol anchor secured the device in the jugular. The RV lead was
positioned in the RV apex and screwed into place. The catheters, wires, and sheath were removed with an
average implant time of 14 minutes. In one group of animals (n = 13), serial venograms were performed
at 7 days, 14 days, and 28 days. In a second group (n = 6) and third group (n = 5), venograms were
also performed at 90 days and 270 days, respectively. Six canines were sacrificed and anchor histologic
examination done at 90 days.
Results: All implants were successful with no surgical complications observed. Devices (N = 24)
remained appropriately positioned with no anchor migration. Histology at 90 days showed 98%
endothelialization of the anchor. Venograms revealed patent IVC and jugular veins in all animals at
every time point examined.
Conclusions: The PICD can be rapidly and chronically implanted in animals. Long-term intravascular
defibrillator placement is feasible in a canine model. (PACE 2013; 36:1251–1258)
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Introduction
A percutaneously placed implantable
cardioverter defibrillator (PICD) has been
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developed which has shown superior
defibrillation thresholds (DFTs) when compared
to conventional devices in animal models.1 The
device utilizes a unique defibrillation vector
that includes the inferior-posterior segments
of the right ventricle, shocking from a right
ventricular coil (anode) to titanium cans located
in the superior vena cava (SVC) and inferior
vena cava (IVC), respectively (Figs. 1A and B).2
The PICD is rapidly implanted (average of 14
minutes) from the femoral vein and designed to be
completely removed when explant or replacement
is required.1 The device has a 4.5-year battery
life and removal is by an entirely percutaneous
technique, which has recently been described.3
Despite multiple studies as well as guidelines
recommending ICD placement for primary preven-
tion, it is estimated that up to 60% of patients
©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.
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Figure 1. (A) Percutaneous intravascular defibrillator
(PICD) with right ventricular lead system. (B) Typical
position of PICD in the canine venous vasculature.
Arrows mark the anchoring region and caudal aspect of
the device in the left external jugular vein and inferior
vena cava, respectively.
eligible for this potentially life-saving therapy go
untreated.4–7 The reasons for underutilization of
the ICD in this population remains uncertain and
a topic of vigorous debate.8 The requirements of
a surgical procedure and implantation by highly
trained subspecialist may play a role.4
A percutaneously placed, intravascular de-
vice could provide certain technical implantation
advantages and reduce specific surgical complica-
tions, but little is known regarding venous device
compatibility. This study evaluated the implant
techniques, device stability, vessel patency, and
anchor histology of the PICD over 9 months in a
canine model.
Methods
This study was approved by the Synecor
Institutional Animal Use and Care Committee
and The Arrhythmia Research Foundation of
Semmelweis University prior to its initiation.
Study Design
Three groups of canines were studied based
on the timing and total number of venograms that
were obtained in each animal. The first group of
the canines (Group 1, n= 13) had serial venograms
performed at 7 days, 14 days, and 28 days. In
the second group (Group 2, n = 6) and the third
group (Group 3, n = 5), venograms were also
performed at 90 days and 270 days, respectively. A
total of 24 canines were implanted and underwent
evaluation. Six canines (Group 2) were sacri-
ficed and anchor histologic examination done at
90 days.
Surgical Preparations and Monitoring
All animals were sedated with a 5.5-
mg/kg bolus of ketamine and 0.275 mg/kg of
diazepam. Canines were intubated and ventilated
(FG- Hallowell EMC model 2000 ventilator,
Hallowell EMC, Pittsfield, MA, USA). Anesthesia
was maintained using inhaled 1–5% isoflurane
supplemented with 100% oxygen. Jaw relaxation
was monitored to ensure the appropriate level
of anesthesia. Femoral arterial pressure and
surface electrocardiogram lead II were monitored
continuously.
Device Positioning and Electrode Configuration
A 27Fr custom sheath (InnerPulse model
13427–01-A, InnerPulse Inc., Research Triangle
Park, NC, USA), which allowed rapid exchange
of multiple catheters through a single port,
was placed in the right femoral vein using the
Seldinger technique. Placement of the InnerPulse
sheath was entirely percutaneous and required no
cut down of the vessel. In a similar fashion, a
6Fr sheath (model no. 406112, St. Jude Medical,
Minnetonka, MN, USA) was positioned in the left
femoral artery and arterial pressure monitoring
was performed via this access. After sheath
placement, a bolus of 2,000 units of heparin was
administered. Two custom guidewires (260 cm,
0.035′′, Lake Region Medical, Inc., Chaska, MN,
USA) were positioned in the left external jugular
vein (LEJV) using a 9Fr standard guide catheter.
The PICD (InnerPulse models #12529–34-A or
#12529–38-A, InnerPulse Inc.) was advanced over
one wire from the right femoral vein such that the
titanium electrodes (cathodes) were located in the
SVC and IVC (Figs. 1 and 2). The SVC electrode
was positioned close to the brachiocephalic-SVC
junction in the cephalic portion of the SVC.
The IVC electrode was located just below the
right atrium at the level of the diaphragm. The
right ventricular (RV) lead (model #12529–38-A,
InnerPulse Inc.) was introduced with a delivery
catheter (model #13554–1, InnerPulse Inc.) into
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Figure 2. Fluoroscopy of the percutaneously placed
implantable cardioverter defibrillator body and right
ventricular lead in the canine heart.
Figure 3. Interaction of the silicone rubber cephalic an-
choring area of the percutaneously placed implantable
cardioverter defibrillator with the nitinol anchor.
the femoral vein, advanced to the heart through
the usual course, positioned in the apex of the right
ventricle, and screwed into place. Over the second
wire, a self-expanding nitinol anchor (InnerPulse
model #13521 or #13617, 13–18 mm, InnerPulse
Inc.) was advanced to the LEJV and deployed
over the PICD cephalic tip, securing the device to
the vessel wall (Fig. 3). Anchor size was chosen
to achieve between 15% and 45% oversizing
of the vessel from the baseline measurement of
LEJV diameter. All catheters, wires, and sheaths
were removed. Hemostasis was achieved and all
canines fully recovered from the procedure.
Stability and Migration Evaluation
Anchor stability was evaluated using relative
changes in the anchor location as demonstrated
with fluoroscopic/cineographic imaging. Care was
taken to ensure that each animal was reproducibly
positioned in an anterior-posterior position. The
animal was positioned on the procedure table in a
dorsally recumbent position with lateral external
rotation of the forelimbs. Initial implant location
was documented in reference to boney structures
with the animal appropriately positioned. The
line of reference was a perpendicular line to the
target vessel between the shoulder girdle and
the adjacent vertebrae. Relative anchor migration
>2 cm by fluoroscopic examination was consid-
ered significant.
Angiographic Luminal Patency
Angiography (venography) was employed to
evaluate luminal patency of all vessels examined
at each time point. At implant, venograms were
obtained initially with the injection catheter posi-
tioned in the LEJV just proximal to the deployed
anchor and, subsequently, proximal to the bottom
of the PICD located in the IVC (Figs. 4A and 5A).
At appropriate time intervals for each group of
canines, peripheral upper extremity venograms
and catheter injection venograms were obtained to
determine continued patency of the LEJV anchor
region and the IVC, respectively (Figs. 4A and
B and 5A and B). Any obstruction >70% was
deemed significant and all measurements were
compared to baseline.
Anchor Site Tissue Evaluation
In the group of six canines sacrificed at 90
days, histopathology of the anchoring region was
performed to establish safety based on appropriate
vessel healing without evidence of significant
hemorrhage or vein perforation. Tissues surround-
ing the point of anchor placement were examined
to determine the degree, if any, of collateral
injury to adjacent organs or structures. In addition,
the target vessel patency was histopathologically
determined.
Histopathology Preparation
All gross necropsies were performed under
the supervision of a board-certified veterinary
pathologist. The LEJV anchoring region was
exposed and an adequate vascular segment, which
incorporated the anchor and the silicone superior
tip of the PICD device, was removed. The vascular
segment included >1 inch of marginal vascular
tissue both distal and proximal to the implanted
anchor. All tissues for histology assessment were
stored in 10% buffered formalin and sent to the
histology laboratory where the tissue trimming
was performed.
Histology Evaluation, Light Microscopy,
and Staining
Tissues were stained with hematoxylin and
eosin prior to evaluation by light microscopy.
Light microscopy was also performed on tissue
sections taken adjacent, subjacent, or distal to the
implant site to determine and characterize cellular
changes.
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Figure 4. Anchor and cephalic portion of the percutaneously placed implantable cardioverter defibrillator with
venograms at implant and 9 months. (A) Venogram at the time of implant. (B) Upper extremity venogram showing
patent anchor and normal venous vasculature at 9 months.
Anchor: Tissue Processing
The explanted vascular segment containing
the anchor was submitted intact for histopatho-
logic assessment. The vascular segment was
trimmed with sufficient margins to maintain
the integrity of the areas of interest. Each
vascular segment was embedded in plastic, cross-
sectioned, and stained. Inclusion of anchor and
tissues in polymethymethacrylate permitted thin
slides and preserved the capacity to perform the
appropriate staining.9 The vascular segment was
cross-sectioned in a minimum of four segments.
The segments were evaluated for inflammation,
capsule fibrosis, hemorrhage, endothelialization,
necrosis, and luminal patency.
Results
Implantation and Positioning
The PICD was successfully implanted on the
first attempt in all animals. Appropriate electrode
positioning was achieved in all cases with anchor
deployment in the LEJV. RV leads were screwed
into locations in the apex or septum. There were
no acute dislodgements of the anchor or lead.
The average implantation time for this device
is 14.3 ± 4.9 minutes (range 7–24 minutes).
The time for implantation does not include that
which is required for assessment of DFT or pacing
parameters.
General Health
Canines were formally examined by a veteri-
narian weekly and were observed daily to detect
any change in behavior. All canines were deemed
in excellent health during the duration of the trial.
Baseline and Follow-Up Venograms
Venography was performed at baseline fol-
lowing completion of the implant procedure.
Measurements of vessel diameter at the site of
the anchor and the IVC at the level of the
base of the PICD were obtained. All subsequent
diameter evaluations at specified time points were
compared to baseline. Venograms demonstrated
widely patent LEJVs and IVCs in all animals at
all times point tested (Figs. 4A and B and 5A
and B). When compared to implant position, no
significant movement of any anchor was observed
and all PICDs remained in the same position.
In Group 2 (n = 6) of canines, which were
sacrificed at 90 days, formal vessel measurement
comparisons were calculated and are shown in
Tables I and II.
Anchor Histopathology
A veterinary pathologist directed all tissue
preparation and performed all histopatholgic
evaluations. In the six canines sacrificed at 90
days, necropsy and gross evaluation showed no
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Figure 5. Venograms of inferior vena cava with percu-
taneously placed implantable cardioverter defibrillator
(PICD) in appropriate position at implant and 9months.
(A) Implant. (B) Nine months postimplant. Distal
venous system is normal. Persistent slight dilatation
of the IVC, which contains the PICD. No evidence of
thrombosis or collateral formation.
evidence of anchor perforation, blood extrava-
sation, or damage to surrounding tissues. The
anchors and device tip-anchoring region were en-
cased in a fibrosis capsule. Vein lumen was patent
in all instances with no microscopic evidence of
perforation or blood in vessel wall or surrounding
tissues (Fig. 6). This finding was confirmed in
both gross and histopathology evaluations. The
histopathologic examination demonstrated that
greater than 98% of all anchor wires were
endothelialized and were covered with a mature
neointima composed of collagenous fibrovascular
tissue generally between 0.1-mm and 1-mm thick.
No significant inflammation was observed (Fig. 6).
Discussion
Implantable defibrillators are proven to re-
duce mortality when employed as primary pre-
vention in heart failure patients; however, this life-
saving therapy remains underutilized in the target
population. The development of a percutaneously
placed device, requiring no surgical technique,
which can be achieved more rapidly than con-
ventional ICD insertion, could potentially impact
acceptance of this therapeutic approach. The PICD
has a battery life of 4.5 years and, because of
its unique totally intravascular location, implan-
tation and removal techniques were developed
simultaneously.3 R-wave determination, pacing
thresholds, and ventricular fibrillation induction
are performed via a hand-held programmer, which
has a wireless telemetry range of 6–8 feet. The time
required to evaluate typical pacing parameters
and DFT is 3–5 minutes.1,10 At the end of
battery life, the device can be removed and a
second PICD placed in a similar location. The
PICD consists of a series of isodiametric titanium
cans connected at manufacturing to an RV lead
(Fig. 1A). It represents, to our knowledge, the first
defibrillator and lead system specifically designed
to be removed.
Venous access was attained utilizing a custom
27Fr sheath in this animal study. In order to ensure
adequate hemostasis in these active canines, the
vessels and wounds were sutured after sheath
removal. No significant groin complications were
observed in any animal. A human trial of 10
patients using the same sheath has demonstrated
excellent venous hemostasis with 20 minutes of
manual compression without a closure device
or other intervention.10 One minor hematoma
occurred, which resolved by day 7 postprocedure
and required no therapy.10
The isodiametric form factor allows the
device, when snared from below, to torque in a
1:1 fashion unlike conventional leads. The RV
lead has a detachment region just proximal to the
screw, which permits lead removal by traction
from the IVC without the use of laser, radiofre-
quency, or extraction sheaths. All pacemaker
and defibrillator leads are to varying degrees
encapsulated in fibrosis tissue and subsequently
either totally or partially endothelialized.11–13 At
points of wall contact, neointimal proliferation
and calcification can occur.14 The PICD has been
observed to freely float in the venous blood
pool, touching only at the anchoring site and the
RV apical screw. The body of the device and
lead do experience typical thin fibrosis tissue
encapsulation. The isodiameteric form factor and
the ability to torque allow sliding if neointimal
proliferation or adhesion does occur.
For removal, the IVC segment of the PICD is
snared utilizing a custom catheter. The RV lead is
separated from the body of the PICD by cutting the
lead inside a protective sheath. A novel catheter
with a surgical cutting wire is then advanced over
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Table I.
LEJV-Original Diameter, Degree of Oversizing with Anchor, Patency, and Diameter at 45 Days and 90 Days
Postimplantation
45 Days 90 Days
Baseline Follow-Up Follow-Up
OD IID OD IID IID Device Functional Functional 45 Days Functional 90 Days
Device Target Anchor Lumen Lumen Luminal Lumen Luminal
Anchor Vessel Size Diameter Diameter Patency Diameter Patency
Animal # Location (mm) (mm) % OS (mm) (mm) (%) (mm) (%)
D-481 LEJV 8.2 11 134.1 8.9 10.7 119.6 10.5 117.3
D-482 LEJV 9.8 13 132.7 9.2 12.2 132.6 13.0 141.9
D-483 LEJV 7.7 11 142.9 8.2 11.1 136.3 10.7 130.5
D-479 LEJV 8.7 11 126.4 8.7 11.3 129.4 10.6 121.4
D-506 LEJV 9.4 13 138.3 10.3 12.1 116.7 12.3 119.4
D-509 LEJV 11.0 15 136.4 10.3 12.7 123.3 14.0 135.7
Mean 9.1 135.1 9.3 11.7 126.3 11.8 127.7
SD 1.2 5.5 0.9 0.8 7.7 1.5 9.9
LEJV = left external jugular vein; SD = standard deviation.
Table II.
IVC Patency and Diameter at 45 Days and 90 Days Postimplantation of PICD
Baseline IVC 45 Days IVC 45 Days Luminal 90 Days IVC 90 Days Luminal
Animal # Diameter (mm) Diameter (mm) Patency (%) Diameter (mm) Patency (%)
D-481 15.9 15.0 94.6 17.8 112.5
D-482 13.5 15.9 118.1 21.2 157.6
D-483 12.8 13.6 106.2 18.9 147.0
D-479 12.8 17.0 132.7 18.9 147.9
D-506 16.3 15.4 94.5 20.4 125.0
D-509 17.7 21.0 118.3 19.5 109.9
Mean 14.8 16.3 110.7 19.5 133.3
SD 2.1 2.5 15.1 1.2 20.2
IVC = interior vena cava; PICD = percutaneously placed implantable cardioverter defibrillator; SD = standard deviation.
the device. The PICD acts as a rail to advance
the cutting wire to the anchoring region. The
silicone segment of the PICD is detached from
the nitinol anchor by the cutting catheter and the
entire device is removed via the femoral vein.
Subsequently, the RV lead is snared. A cutting
wire is positioned at a specific detachment region
at the tip and the lead is cut and removed through
the femoral vein. After device removal, a newPICD
can be placed and this procedure has been safely
performed in the canine model.
This removal technique employs separation
of the lead and anchoring segments by cutting
with either a surgical wire or custom intravascular
scissors. In order to perform this operation safely,
all cutting takes place either inside a sheath
or with the device serving as a rail to guide
the tool. Although not observed in this trial,
vein entrapment or adhesion in the area of
cutting could result in vessel damage and possible
hemorrhage or thrombosis. Careful fluoroscopic
examination of the site prior to tool engagement is
important to ensure proper location and that the
PICD is freely floating in the vascular space. This
removal procedure requires less than 20 minutes
and has been performed in canines (N = 10) by
independent operators with no complications.3
Minor variability was observed in time required
for removal of the PICD between operators. The
difference appeared dependent on a learning curve
for the procedure as well as the RV lead position.
Benefits of such a percutaneous system might
include the elimination of many of the factors
that have traditionally contributed to lead and
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Figure 6. Histologic sections at 3 months postimplant through anchor in two canines showing silicone rubber
percutaneously placed implantable cardioverter defibrillator (PICD) tip in stable position and secured. Vein is widely
patent in anchoring region. (A) Middle portion of anchor. Black struts of anchor are evident and confined within
the vein wall. No evidence of perforation. Yellow PICD tip pressed against wall in appropriate position. (B) High
magnification showing endothelialization of anchor wires. Black struts of anchor are evident and confined within
the vein wall. No evidence of perforation. (C) Cranial aspect of the anchor and PICD tip. No evidence of perforation.
Yellow PICD tip pressed against wall in appropriate position with tines visible.
device complications. The PICD lead is not subject
to pocket insulation erosion, loose setscrews,
subclavian crush, or the forces that result in
lead perforation due to its unique attachment to
the device and lead location in the vasculature.
Device pocket infection or erosion are not possible
and there is an obvious cosmetic and comfort
advantage for the patient.
Stents in the large veins have been employed
to treat a variety of disorders, including Budd-
Chiari syndrome and obstructive thrombosis.15–17
In the IVC, stents have been effectively po-
sitioned for the treatment of thrombosis in a
vena caval filter.18 More recently, caval stents
have anchored valves for therapy of severe
tricuspid regurgitation.19 However, little is known
concerning the long-term vascular response of
stenting normal venous structures and even less
is understood about employing veins to anchor
or secure a medical device. This trial evaluates
the anchor vascular effects and histopathologic
vessel response to the placement of a percutaneous
defibrillator, which is held in place by a nitinol
anchor.
This trial showed minimal venous vascular
response to the anchoring stent in the LEJV.
The anchor uniformly maintained the PICD in
the implanted position and all venous structures
remained widely patent. Histopathologic exam-
ination of anchor region showed incorporation
of the anchor into the venous wall and near-
complete endothelialization of the wire struts.
No damage to surrounding tissues was seen. The
LEJV at the level of the anchor at 3 months
maintained the oversizing range that was targeted
at implant (Table I). The IVC shows modest
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dilatation throughout the course of the PICD
(Table II).
Conclusions
The PICD can be securely anchored in the
canine venous vasculature and has no deleterious
effects on the vessel or surrounding tissue. Nitinol
anchors similar to stents can be placed in veins
and rapidly incorporated into the vessel wall
and their lumen surfaces endothelialize within
3 months. Vein patency is maintained with an
implanted PICD in a canine model.
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